The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task

REFERENCES

• Ali, E. H. & Arafa, N. M. (2011). Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction. Fitoterapia, 82, 601–608.
   Google Scholar
• Andreeva, S. G., Dikkes, P., Epstein, P. M. & Rosenberg, P. A. (2001). Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci, 21, 9068–9076.
   Google Scholar
• Bentley, P., Driver, J. & Dolan, R. J. (2011). Cholinergic modulation of cognition: Insights from human pharmacological functional neuroimaging. Prog Neurobiol, 94, 360–388.
   PubMed Web of Science ®Google Scholar
• Bonkale, W. L., Winblad, B., Ravid, R. & Cowburn, R. F. (1995). Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett, 187, 5–8.
   Google Scholar
• Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C. & Stahl, S. M. (1988). Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia, 26, 685–700.
   PubMed Web of Science ®Google Scholar
• Castoldi, A. F., Manzo, L. & Costa, L. G. (1993). Cyclic GMP formation induced by muscarinic receptors is mediated by nitric oxide synthesis in rat cortical primary cultures. Brain Res, 610, 57–61.
   PubMed Web of Science ®Google Scholar
• Chamberlain, S. R., Muller, U., Robbins, T. W. & Sahakian, B. J. (2006). Neuropharmacological modulation of cognition. Curr Opin Neurol, 19, 607–612.
   PubMedGoogle Scholar
• Cools, R. & D’Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry, 69, 113–125.
   PubMed Web of Science ®Google Scholar
• Dalley, J. W., Cardinal, R. N. & Robbins, T. W. (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev, 28, 771–784.
   PubMed Web of Science ®Google Scholar
• de Vente, J. (2004). cGMP: A second messenger for acetylcholine in the brain? Neurochem Int, 45, 799–812.
   PubMed Web of Science ®Google Scholar
• Domek-Lopacinska, K., van de Waarenburg, M., Markerink-van Ittersum, M., Steinbusch, H. W. & de Vente, J. (2005). Nitric oxide-induced cGMP synthesis in the cholinergic system during the development and aging of the rat brain. Brain Res Dev Brain Res, 158, 72–81.
   Google Scholar
• Domek-Lopacinska, K. U. & Strosznajder, J. B. (2010). Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol, 41, 129–137.
   PubMed Web of Science ®Google Scholar
• Drachman, D. A. & Leavitt, J. (1974). Human memory and the cholinergic system. A relationship to aging? Arch Neurol, 30, 113–121.
   PubMed Web of Science ®Google Scholar
• Fisher, D. A., Smith, J. F., Pillar, J. S., St Denis, S. H. & Cheng, J. B. (1998). Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem, 273, 15559–15564.
   PubMed Web of Science ®Google Scholar
• Foldi, N. S., White, R. E. & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. Int J Geriatr Psychiatry, 20, 485–488.
   PubMed Web of Science ®Google Scholar
• Harada, N., Nishiyama, S., Ohba, H., Sato, K., Kakiuchi, T. & Tsukada, H. (2002). Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys. Synapse, 44, 139–145.
   Google Scholar
• Hilbig, H., Holler, J., Dinse, H. R. & Bidmon, H. J. (2002). In contrast to neuronal NOS-I, the inducible NOS-II expression in aging brains is modifled by enriched environmental conditions. Exp Toxicol Pathol, 53, 427–431.
   Google Scholar
• Hutson, P. H., Finger, E. N., Magliaro, B. C., Smith, S. M., Converso, A. & Sanderson, P. E., . (2011). The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology, 61, 665–676.
   PubMed Web of Science ®Google Scholar
• Jesko, H., Chalimoniuk, M. & Strosznajder, J. B. (2003). Activation of constitutive nitric oxide synthase(s) and absence of inducible isoform in aged rat brain. Neurochem Int, 42, 315–322.
   Google Scholar
• Karasawa, J., Hashimoto, K. & Chaki, S. (2008). D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res, 186, 78–83.
   PubMed Web of Science ®Google Scholar
• Lakics, V., Karran, E. H. & Boess, F. G. (2010). Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology, 59, 367–374.
   PubMed Web of Science ®Google Scholar
• Levin, E. D., Bushnell, P. J. & Rezvani, A. H. (2011). Attention-modulating effects of cognitive enhancers. Pharmacol Biochem Behav, 99, 146–154.
   PubMed Web of Science ®Google Scholar
• Liu, P., Smith, P. F., Appleton, I., Darlington, C. L. & Bilkey, D. K. (2005). Hippocampal nitric oxide synthase and arginase and age-associated behavioral deficits. Hippocampus, 15, 642–655.
   Google Scholar
• Mirza, N. R., Peters, D. & Sparks, R. G. (2003). Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev, 9, 159–186.
   PubMedGoogle Scholar
• Molchan, S. E., Martinez, R. A., Hill, J. L., Weingartner, H. J., Thompson, K., Vitiello, B., . (1992). Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev, 17, 215–226.
   PubMedGoogle Scholar
• Pitsikas, N. & Sakellaridis, N. (2007). Memantine and recognition memory: Possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine. Eur J Pharmacol, 571, 174–179.
   Google Scholar
• Reneerkens, O. A., Rutten, K., Steinbusch, H. W., Blokland, A. & Prickaerts, J. (2009). Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl), 202, 419–443.
   PubMed Web of Science ®Google Scholar
• Reyes-Irisarri, E., Markerink-Van Ittersum, M., Mengod, G. & de Vente, J. (2007). Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur J Neurosci, 25, 3332–3338.
   PubMed Web of Science ®Google Scholar
• Robbins, T. W. (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl), 163, 362–380.
   PubMed Web of Science ®Google Scholar
• Rezvani, A. H. & Levin, E. D. (2004). Nicotine-antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol, 486, 175–182.
   PubMed Web of Science ®Google Scholar
• Schliebs, R. & Arendt, T. (2006). The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm, 113, 1625–1644.
   PubMed Web of Science ®Google Scholar
• Shimazaki, T., Kaku, A. & Chaki, S. (2010). D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl), 209, 263–270.
   Google Scholar
• Smith, J. W., Gastambide, F., Gilmour, G., Dix, S., Foss, J., Lloyd, K., . (2011). A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl).
   Google Scholar
• Swartz, B. E. & Woody, C. D. (1979). Correlated effects of acetylcholine and cyclic guanosine monophosphate on membrane properties of mammalian neocortical neurons. J Neurobiol, 10, 465–488.
   Google Scholar
• Tonnaer, J. A., Cheung, C. L. & De Boer, T. (1991). cGMP formation and phosphoinositide turnover in rat brain slices are mediated by pharmacologically distinct muscarinic acetylcholine receptors. Eur J Pharmacol, 207, 183–188.
   Google Scholar
• Vallebuona, F. & Raiteri, M. (1995). Age-related changes in the NMDA receptor/nitric oxide/cGMP pathway in the hippocampus and cerebellum of freely moving rats subjected to transcerebral microdialysis. Eur J Neurosci, 7, 694–701.
   Google Scholar
• Van Dam, D., Abramowski, D., Staufenbiel, M. & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl), 180, 177–190.
   PubMed Web of Science ®Google Scholar
• van der Staay, F. J., Rutten, K., Barfacker, L., Devry, J., Erb, C., Heckroth, H., . (2008). The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 55, 908–918.
   PubMed Web of Science ®Google Scholar
• Van Staveren, W. C., Steinbusch, H. W., Markerink-Van Ittersum, M., Repaske, D. R., Goy, M. F., Kotera, J., . (2003). mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol, 467, 566–580.
   PubMed Web of Science ®Google Scholar
• Williams, G. V. & Castner, S. A. (2006). Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience, 139, 263–276.
   PubMed Web of Science ®Google Scholar
• Wise, L. E. & Lichtman, A. H. (2007). The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task. Eur J Pharmacol, 575, 98–102.
   PubMed Web of Science ®Google Scholar
• Yu, W., Juang, S., Lee, J., Liu, T. & Cheng, J. (2000). Decrease of neuronal nitric oxide synthase in the cerebellum of aged rats. Neurosci Lett, 291, 37–40.
   Google Scholar